Oculis Holding AG (OCS) Form 6-K — May 14, 2026
Oculis Holding AG reported the results of its 2026 Annual General Meeting, where shareholders approved all agenda items, including the 2025 financial statements which showed a standalone statutory loss of CHF 33.7 million and an accumulated balance sheet loss of CHF 80.2 million. Gregory D. Perry, former CFO of Merus N.V. and Finch Therapeutics, was elected as a new member of the Board of Directors, bringing extensive experience in US capital markets and biotech governance to the company.
Key figures
- Loss
- CHF 33,670,000
- Accumulated Loss
- CHF 80,247,000
- Capital Band Shares
- 31,020,888
- Treasury Shares Issued
- 5,750,400
- Capital Band Lower Limit
- CHF 620,417.76
- Capital Band Upper Limit
- CHF 930,626.64
- Exec Compensation Fixed
- USD 2,500,000
- Total Registered Shares
- 67,792,176
- Board Compensation Fixed
- USD 572,000
- Exec Compensation Equity
- USD 18,000,000
- Board Compensation Equity
- USD 2,150,000
- Exec Compensation Variable
- USD 1,800,000
- Conditional Capital Employee Value
- CHF 126,777.00
- Conditional Capital Employee Shares
- 12,677,700
- Treasury Ownership Percent
- 9.15%
- Shares Issued Warrant Exercise
- 2,077,288
- Shares Issued Equity Settlement
- 795,013
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.